Shareholders of Rocket Pharmaceuticals, Inc. Should Be Aware of Class Action Lawsuit Deadline

Class Action Lawsuit Alerts Investors of Rocket Pharmaceuticals, Inc.

The Gross Law Firm has issued a critical notice for shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), reminding them of an impending class action lawsuit. This lawsuit arises from serious allegations regarding misleading statements made by the company about the safety and protocol of their clinical trials. The deadline for potential lead plaintiffs is set for August 11, 2025.

Allegations Against Rocket Pharmaceuticals

The class action is centered around the claims that Rocket Pharmaceuticals provided overly optimistic statements to investors while concealing significant adverse information related to its RP-A501 clinical trial. Notably, it has come to light that the firm was aware of Serious Adverse Events (SAEs), including the deaths of trial participants, and failed to disclose this vital information to shareholders.

This lack of transparency was exacerbated when the company amended the trial protocol to include a new immunomodulatory agent, which they neglected to disclose to investors at the time of the amendment. As a result, investors purchased shares at artificially inflated prices, only to face a subsequent decline following the revelation of these serious issues.

On May 27, 2025, Rocket Pharmaceuticals announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 trial after a participant suffered a SAE that led to death. This news caused Rocket's stock price to tumble, dropping sharply from $6.27 per share on May 23, 2025, to $2.33 per share just days later, representing a staggering decline of approximately 37% within a single trading day.

Next Steps for Shareholders

Affected shareholders are strongly encouraged to register with The Gross Law Firm to potentially become lead plaintiffs in the class action lawsuit. By registering, shareholders will be enrolled in a portfolio monitoring system that will keep them updated throughout the case’s development. Importantly, there’s no cost or obligation associated with participating in this case, making it a viable option for those affected by the recent downturn.

The firm emphasizes their commitment to protecting the rights of investors who have suffered losses due to deceptive practices and misinformation. Interested parties can find more details and complete the necessary registration through the Gross Law Firm's website.

Why Choose The Gross Law Firm?

The Gross Law Firm is a well-renowned class action law firm in the United States, dedicated to advocating for investors impacted by corporate misconduct. Their track record demonstrates a commitment to achieving justice and compensation for shareholders who have experienced losses due to misleading statements and fraud.

This class action presents a critical opportunity for shareholders of Rocket Pharmaceuticals to reclaim their investments and hold the company accountable for its actions. As the deadline approaches, it becomes imperative for affected investors to act promptly to ensure their involvement in this important legal action.

Conclusion

In summary, the ongoing class action lawsuit against Rocket Pharmaceuticals underscores the importance of transparency and honesty in corporate communication. Shareholders should remain vigilant and proactive in protecting their rights, particularly in light of the serious allegations facing the company. The Gross Law Firm remains prepared to assist investors seeking resolution and recovery in this case as it develops into a pivotal moment for Rocket Pharmaceuticals and its shareholders.